Gastrointestinal angiodysplasia: find the source, explain the recurrence
Connect fragile intestinal vessels to painless bleeding, small-bowel testing, Heyde syndrome, endoscopic treatment and prevention of recurrent blood loss.
A red vascular patch and a bleeding patient are not automatically the same diagnosis. The central question is whether fragile intestinal vessels explain the blood loss, what makes bleeding persist, and which action fits the patient's condition now.
By the end, distinguish a superficial vascular lesion from an injured diverticular artery, select tests for active versus intermittent bleeding, explain the valve-related hemostatic defect, and match treatment to the burden of recurrence. The complete lesson is visible below. Prediction checks are optional and do not control access to the next section.
Painless bleeding still needs a source
Angiodysplasia, often called angioectasia, consists of acquired dilated, tortuous, thin-walled vessels in the gastrointestinal lining and underlying submucosa. It commonly becomes clinically important in older adults. Blood loss may be invisible until iron stores fall, or appear as recurrent maroon stool, hematochezia, or melena. The absence of pain describes the presentation; it does not establish the cause or make severe bleeding safe. [1][2][3]
At endoscopy, look for a flat or slightly raised red patch with fine branching vessels. Recognition identifies a candidate lesion. Active oozing, recent bleeding signs, a compatible pattern, and evaluation of competing sources determine whether it explains the episode. A patient can have both an incidental angioectasia and another bleeding lesion.
Endoscopic vascular pattern, not proof of a bleeding source. The archive conflicts about anatomical site, so no site is assigned here. Image: Joachim Guntau / Wikimedia Commons; CC BY-SA 3.0. Image source.
Look, then decide: describe the pictured patch as a network or as a crater with a single vessel. The branching surface pattern supports a vascular ectasia. That observation alone cannot tell you whether the patient is actively bleeding, how much blood was lost, or where this particular image was obtained.
Find the feature that distinguishes the source
Finding
Interpretation
FindingFlat vascular tuft with oozing
InterpretationAngioectasia is a supported culprit.
FindingBleeding vessel at a diverticulum
InterpretationDiverticular arterial bleeding, often abrupt and painless.
FindingCramping followed by blood with segmental injured mucosa
InterpretationConsider ischemic colitis rather than attributing everything to an incidental tuft. [16]
FindingIron deficiency with a mass or new bowel-habit change
InterpretationEvaluate colorectal neoplasia; a previous vascular lesion does not explain away new findings.
These are comparisons, not absolute rules based on pain or stool color. A brisk upper gastrointestinal hemorrhage can also cause hematochezia. The patient's physiology and the observed lesion matter more than a remembered association. [3]
A cecal tuft is dry, but a sigmoid diverticulum is spurting. Which finding should direct treatment?
The observed diverticular hemorrhage provides direct source evidence. Treat that culprit rather than choosing the cecal tuft because it resembles the topic of this lesson. Transfer the same principle to a bleeding ulcer found alongside vascular ectasias.
Why a shallow lesion can bleed repeatedly
The relevant abnormality is vessel dilation near the bowel surface, not blockage of the main intestinal arterial supply. Thin-walled channels can leak into the lumen without the tissue injury that usually produces prominent pain. Bleeding may stop temporarily while the vascular lesion remains, explaining why a quiet examination and a later recurrence can both be genuine. [1][2]
Vessel caliber is exaggerated to show the superficial network. [1][2]
Trace the drawing: follow the enlarged vessel from the submucosa toward the mucosa. Now predict what local surface coagulation can accomplish. It can treat accessible abnormal vessels; it does not prove that every lesion elsewhere has disappeared or that the patient's hemostatic problem has resolved.
The cecum and ascending colon are classic sites, and lesions can be multiple. One historical explanation proposes that intermittent impediment to venous outflow during bowel-wall contraction gradually dilates the submucosal and then mucosal vessels. The relatively large cecal radius and wall tension help frame that hypothesis. This is a proposed degenerative model, not a demonstrated explanation for every lesion or a diagnostic test. [1][2]
Colonic angiodysplasia, PAS stain. Compare the irregular thin-walled spaces with surrounding glandular tissue. This is microscopy, not endoscopy. Image: CoRus13 / Wikimedia Commons; CC BY-SA 4.0. Image source.
In the micrograph, compare the irregular vascular spaces with the nearby glandular tissue. The useful relationship is abnormal vessels within superficial bowel tissue. Histology illustrates that relationship; routine biopsy of a bleeding vascular lesion is not required to establish an endoscopic diagnosis.
The right colon is a common location, not a boundary. Angioectasias also occur in the small bowel and upper gastrointestinal tract. Recurrent unexplained iron loss after adequate upper endoscopy and colonoscopy therefore calls for a small-bowel assessment when clinically indicated, not a declaration that gastrointestinal bleeding has been excluded. [4][5]
A treated cecal lesion is quiet, but later testing finds several jejunal lesions. Was the original treatment necessarily ineffective?
No. Local hemostasis may have succeeded at the cecal site. The new evidence identifies a different distribution of potential sources. Reassess the bleeding location and burden before repeating the same procedure.
Why a valve disorder can worsen intestinal bleeding
Finding the lesion answers where blood can escape. A second question is why a platelet plug fails to hold there. In Heyde syndrome, aortic stenosis is associated with gastrointestinal bleeding from angiodysplasia and an acquired von Willebrand factor abnormality. Flow through the narrowed valve produces high shear, promoting unfolding and proteolysis of the largest von Willebrand factor multimers. Losing these highly effective adhesion structures weakens platelet attachment at a damaged vascular surface. This is not simply a low platelet count. [6][7]
Von Willebrand factor antigen measures quantity; multimer analysis and functional testing address different properties. A normal antigen concentration, platelet count, or routine coagulation time cannot alone exclude this functional disorder. Selective loss of large multimers explains how enough protein may be present while its adhesive performance is impaired. Specialized testing is interpreted with hematology and the clinical context. [6]
Compare multimer length with platelet attachment as shear changes. [6][7]
Change the valve condition: first predict what will happen to multimer length and platelet attachment when shear increases. Open the matching comparison to see the graphical consequence. Each control works with keyboard or touch, without JavaScript or motion. Compare multimer length and platelet attachment rather than bead counts.
Apply higher valve shear: what happens to adhesion?
Compare multimer length with platelet attachment as shear changes. [6][7]
The valve opening narrows in the model, long multimers become shorter fragments, and fewer platelets attach to the injured surface. High shear increases multimer cleavage; it does not require a fall in the circulating platelet count. Compare this picture with the baseline above.
Relieve the valve gradient: what can recover?
Compare multimer length with platelet attachment as shear changes. [6][7]
When excessive shear is reduced, the large-multimer pattern and adhesion can recover. This does not mean that intestinal lesions have immediately vanished. Close either comparison to return to the baseline view; no lesson content depends on leaving it open.
Valve replacement can reduce recurrent bleeding in appropriately selected patients, but it is not a promise of cure or a substitute for stabilizing acute hemorrhage. A prospective TAVI cohort found that residual paravalvular leakage was associated with recurrent bleeding. Coordinate gastrointestinal, hematology, and valve-team evaluation rather than referring every incidental lesion for valve intervention. [6][7]
Kidney disease is a separate contributor. Advanced renal disease is associated with vascular-ectasia bleeding and can also impair platelet function. A normal platelet count does not measure how well platelets adhere or aggregate. Kidney disease can additionally cause nonbleeding anemia, so falling iron stores, visible blood, and source evaluation remain important. Neither renal disease nor aortic stenosis proves that a vascular lesion caused the current episode. [13][15]
After valve treatment, the multimer pattern improves but melena returns. Does the improved test exclude a gastrointestinal source?
No. Hemostatic improvement and persistent or additional intestinal lesions can coexist. Reassess the bleeding, including the gastrointestinal source and residual valve dysfunction, rather than treating one improved laboratory result as proof that bleeding is impossible.
Choose the test for the bleeding state
First ask whether perfusion is threatened. Hypotension, tachycardia, syncope, poor mentation, or ongoing large-volume blood loss require immediate assessment and resuscitation. Establish intravenous access, obtain blood counts and type-and-crossmatch testing, and provide volume and blood products as clinically indicated. An early hemoglobin concentration may not yet reflect the full loss. Review antithrombotic drugs and involve the appropriate acute-care teams; do not wait for a presumed diagnosis of angiodysplasia before treating shock. [3]
After initial resuscitation, ongoing hemodynamically significant hematochezia often favors CT angiography (CTA) to localize active bleeding rapidly. A positive study can guide catheter angiography and embolization. The patient's ability to undergo imaging safely and local emergency resources determine the exact sequence. Reconsider an upper source when the presentation supports it. A negative CTA during a quiet interval does not exclude an intermittently bleeding lesion. [3]
When the patient is stable and preparation is feasible, colonoscopy can identify the lesion and offer hemostasis. Most hospitalized patients who need colonoscopy do not benefit from an automatic rule requiring it within 24 hours; adequate preparation and clinical circumstances matter. CTA and colonoscopy are therefore complementary tools, not interchangeable tests ordered only by the suspected disease name. [3]
Schematic anatomy, not a localization tool. Capsule examines small-bowel mucosa; enteroscopy can then reach and treat selected lesions. [4][5]
Locate the unexamined region: trace the small-bowel loops between the upper tract and colon. In recurrent bleeding after high-quality upper and lower examinations, capsule endoscopy is a first-line small-bowel investigation when that evaluation is indicated. After an overt episode, earlier capsule evaluation improves yield; ESGE recommends ideally within 48 hours. Device-assisted enteroscopy can then confirm and treat a capsule-localized lesion. [4]
Check what “negative endoscopy” actually means. An incomplete or poorly prepared examination may need targeted repetition; adequate studies do not require routine repetition before capsule testing. Obstructive symptoms or suspected stenosis change the plan: evaluate patency or use appropriate cross-sectional imaging before risking capsule retention. Continued overt or occult loss despite a negative small-bowel evaluation warrants reassessment rather than permanent reassurance. [4][5]
The same patient has a negative CTA when stools clear and a positive capsule study after a later episode. Are the studies contradictory?
No. CTA is particularly useful for an active leak, whereas capsule directly examines the mucosal surface. An intermittent lesion can be present without extravasating at the instant of CT. Transfer this distinction to any source that switches between bleeding and quiet intervals.
Treat a bleeding lesion, not an incidental photograph
Intervention depends on the connection between the lesion and the patient's burden. A small vascular patch found during screening in a patient without bleeding or anemia generally does not require prophylactic ablation. The supporting natural-history study was small; observation is not a prediction of zero lifetime risk. New bleeding or iron deficiency requires a fresh clinical assessment. [11]
For an accessible angioectasia causing ongoing blood loss or clinically important anemia, endoscopic therapy targets the abnormal vessels. Argon plasma coagulation (APC) is a commonly used superficial thermal method. Mechanical treatment, such as a clip, may be appropriate for selected lesions and situations. The choice depends on the lesion, location, and endoscopist's assessment, not an absolute rule that every vascular lesion receives the same device. Thermal injury is especially important to avoid in thin bowel walls. This lesson is not a procedure-setting guide. [3][12]
Endoscopic hemostasis and iron replacement solve different problems. Coagulation may stop further loss from the treated site, but it does not refill depleted iron stores. Use oral or intravenous iron according to tolerance, response, absorption, and clinical need, then follow hemoglobin and iron status. A transfusion decision addresses immediate oxygen-delivery risk and symptoms; it is not a substitute for finding the source or planning iron recovery. [3][12]
Sort three patients: a screening patient with normal hemoglobin belongs in observation; a stable patient with an accessible oozing lesion needs source-directed endoscopic assessment; a patient with continuing major bleeding needs resuscitation and rapid localization. Those differences matter more than the shared label “angiodysplasia.”
Hemoglobin rises after transfusion, but ferritin stays low and recurrent bleeding continues. Has the underlying problem been corrected?
No. The transfusion addresses red-cell deficit, while ongoing loss and depleted stores remain. Reassess the source and replenish iron; use the trajectory of support needs rather than a single improved hemoglobin to judge recovery.
When major active bleeding is localized and cannot be controlled or reached endoscopically, angiographic embolization can provide hemostasis. Its benefits must be weighed against complications, including bowel ischemia. Surgery is reserved for selected refractory cases after accurate localization and multidisciplinary assessment. Removing an empirically chosen segment is a poor strategy when the suspected lesions are scattered through the small bowel. [3][5]
Recurrence requires a broader plan
After apparently successful ablation, ask whether bleeding comes from the same lesion, additional lesions, another disease, or a continuing hemostatic contributor. Document overt episodes, hemoglobin and iron trends, transfusions, intravenous iron, admissions, and repeat procedures. A visually small lesion can still impose substantial cumulative burden. Conversely, multiplicity alone is not an instruction to give systemic treatment to someone without blood loss. [2][12]
Specialist-directed somatostatin-analogue therapy is an option for selected refractory patients whose bleeding continues despite iron replacement and endoscopic treatment. In the 2024 OCEAN trial, long-acting octreotide reduced support requirements compared with standard care, which included endoscopic treatment. The study enrolled 62 patients already requiring substantial support; it did not test routine treatment of incidental lesions. Its primary endpoint combined red-cell units and study-defined parenteral-iron support units, so an improvement cannot be reported as the same number of red-cell units avoided. [8][12]
Thalidomide also reduced recurrent small-intestinal angiodysplasia bleeding in a 2023 placebo-controlled trial. A responder had at least a 50% reduction in bleeding episodes compared with the preceding year, not necessarily complete cessation. Trial benefit does not remove the need to consider toxicity. Peripheral neuropathy, constipation, sedation, and other adverse effects matter, and pregnancy is a contraindication because of severe embryo-fetal harm. U.S. use requires the restricted distribution program and its reproductive precautions; thromboembolic risk also requires individualized assessment. This is a selected refractory-disease option, not a default prescription. These trials do not establish which drug is superior in a head-to-head comparison. [9][10]
Medication review is part of the recurrence plan, but stopping every antithrombotic indefinitely can create a competing danger. Distinguish primary prevention from established cardiovascular indications, and balance rebleeding against stroke or coronary risk with the prescribing team. Acute reversal decisions and long-term resumption decisions are different questions. For cardiac aspirin used in secondary prevention, ACG-CAG advises against interruption when possible. When it has been held, the guideline suggests resumption on the day endoscopic hemostasis is confirmed. This is not a universal restart schedule for anticoagulants or every antiplatelet regimen. [14] In suspected Heyde syndrome, reassess valve disease alongside gastrointestinal care rather than assuming repeat ablation alone addresses every contributor. [3][7]
A drug reduces eight annual bleeding episodes to three. Is that success, cure, or neither under a 50% reduction endpoint?
It is a response under that definition: five fewer episodes out of eight is a 62.5% reduction. It is not a cure because three episodes remain. Carry that distinction into decisions about continued iron support, monitoring, adverse effects, and further source assessment.
Keep three questions separate: Where is the bleeding source? Why does hemostasis fail? What intervention fits the current severity and recurrence burden? A useful plan answers all three without treating any one association as proof.
Independent clinical practice
Case 1
Show answer and explanations for case 1
A. Congestion of rectal portosystemic collaterals (Why this does not fit)
Portosystemic collaterals can bleed in portal hypertension. The observed bleeding vessel lies at the dome of a sigmoid diverticulum, not a rectal collateral. Use the bleeding vessel and anatomical site together.
Reasoning steps for option A
What vascular abnormality produces rectal variceal bleeding?
Portosystemic collaterals can bleed in portal hypertension.
Does the observed source lie in a rectal collateral?
The observed bleeding vessel lies at the dome of a sigmoid diverticulum, not a rectal collateral.
How does the sigmoid bleeding site distinguish this episode from rectal varices?
A spurting vessel at a sigmoid diverticulum identifies a diverticular source, not bleeding from rectal portosystemic collaterals.
B. Injury to a diverticular vasa recta branch (Best answer)
The spurting vessel at the sigmoid diverticulum identifies the active source. Diverticular hemorrhage arises from an injured branch of the vasa recta. The dry cecal lesions do not outweigh direct evidence from the diverticulum.
Reasoning steps for option B
Which lesion has direct evidence of current bleeding?
The spurting vessel at the sigmoid diverticulum identifies the active source.
What type of vessel supplies this lesion?
Diverticular hemorrhage arises from an injured branch of the vasa recta.
How should the dry cecal patches affect attribution?
The dry cecal lesions do not outweigh direct evidence from the diverticulum.
Why attribute this hemorrhage to vasa recta rather than the dry cecal patches?
The diverticular vessel is visibly spurting, providing direct source evidence that the nonbleeding cecal patches lack.
C. Bleeding from an ulcerated colonic neoplasm (Why this does not fit)
An ulcerated tumor can produce occult or visible bleeding. A spurting vessel at a diverticulum accounts for this episode without invoking an unseen tumor. Prefer a demonstrated source over a speculative lesion.
Reasoning steps for option C
How can a colonic neoplasm cause blood loss?
An ulcerated tumor can produce occult or visible bleeding.
What observed lesion accounts for the bleeding here?
A spurting vessel at a diverticulum accounts for this episode without invoking an unseen tumor.
Why is a colonic tumor less supported than the diverticular source?
The examination demonstrates a bleeding diverticular vessel but no ulcerated tumor to account for the episode.
D. Ischemic disruption of segmental colonic mucosa (Why this does not fit)
Pain and segmental injured mucosa support a low-flow inflammatory process. Colonoscopy demonstrates a focal spurting diverticular vessel rather than segmental mucosal injury. A focal arterial source is different from diffuse mucosal damage.
Reasoning steps for option D
What usually directs attention toward ischemic colitis?
Pain and segmental injured mucosa support a low-flow inflammatory process.
What does this examination demonstrate instead?
Colonoscopy demonstrates a focal spurting diverticular vessel rather than segmental mucosal injury.
How does the focal spurting vessel differ from ischemic mucosal bleeding?
The observed source is a focal diverticular artery rather than the segmental mucosal injury expected with ischemic colitis.
E. Rupture of superficial ectatic cecal vessels (Why this does not fit)
An angioectasia can cause painless recurrent blood loss. The observed bleeding arises at a sigmoid diverticulum, while the cecal patches are dry. Source evidence outranks a coincidental vascular appearance.
Reasoning steps for option E
What can a cecal vascular tuft cause?
An angioectasia can cause painless recurrent blood loss.
Where is active bleeding actually seen?
The observed bleeding arises at a sigmoid diverticulum, while the cecal patches are dry.
Why should the cecal ectasias not be labeled the culprit here?
They are dry while active hemorrhage is seen at the sigmoid diverticulum, so their vascular appearance alone does not establish causation.
Takeaway: Treat the demonstrated culprit; multiple findings do not carry equal causal weight.
A. Diagnostic colonoscopy of the current colonic symptoms (Best answer)
Anemia with markedly depleted iron stores requires evaluation for ongoing loss or impaired absorption. New bowel-habit change and weight loss raise concern for a different colonic lesion, including neoplasia. Diagnostic colonoscopy examines the current colon rather than assuming that the old incidental lesion remains the explanation.
Reasoning steps for option A
What do the hemoglobin and ferritin establish?
Anemia with markedly depleted iron stores requires evaluation for ongoing loss or impaired absorption.
Why is the old vascular finding insufficient?
New bowel-habit change and weight loss raise concern for a different colonic lesion, including neoplasia.
Which study addresses that concern directly?
Diagnostic colonoscopy examines the current colon rather than assuming that the old incidental lesion remains the explanation.
What makes current colonoscopy necessary despite the old benign vascular finding?
New constipation, weight loss and iron deficiency require evaluation of the current colon for another lesion, including neoplasia.
B. Von Willebrand factor multimer analysis (Why this does not fit)
Multimer analysis investigates selected functional von Willebrand factor disorders. It does not evaluate a possible structural colonic lesion causing these symptoms. Hemostatic testing cannot replace source assessment.
Reasoning steps for option B
What question does multimer analysis address?
Multimer analysis investigates selected functional von Willebrand factor disorders.
Would it explain the new constipation and weight loss?
It does not evaluate a possible structural colonic lesion causing these symptoms.
Why cannot multimer analysis replace colon evaluation in this patient?
It assesses a hemostatic disorder, not the structural colonic disease suggested by new constipation and weight loss.
C. CT angiography for an active luminal leak (Why this does not fit)
CTA can rapidly localize ongoing significant bleeding. The supplied problem is stable iron deficiency with new bowel-habit symptoms, not an active major leak. Choose a test that addresses the current diagnostic question.
Reasoning steps for option C
What is CTA particularly useful for?
CTA can rapidly localize ongoing significant bleeding.
What limits its usefulness for this question?
The supplied problem is stable iron deficiency with new bowel-habit symptoms, not an active major leak.
Why is an active-leak study poorly matched to her new symptoms?
She has stable iron deficiency without visible ongoing major bleeding; the new bowel-habit change and weight loss call for structural colon evaluation.
D. Serial fecal occult-blood testing during iron treatment (Why this does not fit)
A positive result can indicate gastrointestinal blood loss. Established iron deficiency with new concerning symptoms needs diagnostic evaluation rather than repeated screening tests. Do not use a screening result to defer an indicated structural investigation.
Reasoning steps for option D
What can fecal blood testing indicate?
A positive result can indicate gastrointestinal blood loss.
Why is it not the decisive next investigation here?
Established iron deficiency with new concerning symptoms needs diagnostic evaluation rather than repeated screening tests.
Why should serial occult-blood tests not postpone colonoscopy?
Iron deficiency is already established, and the new constipation and weight loss warrant diagnostic evaluation regardless of another screening result.
E. Capsule endoscopy of the small-bowel mucosa (Why this does not fit)
Capsule endoscopy is useful when small-bowel evaluation is indicated after adequate assessment of accessible sources. The new colonic symptoms and an examination from three years ago justify current colon evaluation. An old vascular diagnosis does not establish a small-bowel source.
Reasoning steps for option E
When is capsule endoscopy useful for bleeding?
Capsule endoscopy is useful when small-bowel evaluation is indicated after adequate assessment of accessible sources.
What new findings need assessment first?
The new colonic symptoms and an examination from three years ago justify current colon evaluation.
Why should the colon be reassessed before a small-bowel capsule study?
Her new symptoms concern the colon, and a colonoscopy three years earlier does not assess the cause of the current presentation.
Takeaway: A previous benign explanation does not explain away new symptoms.
A. High-shear loss of large von Willebrand multimers (Why this does not fit)
Severe aortic stenosis can impair primary hemostasis through multimer cleavage. A hemostatic defect does not itself explain the acute left-colon injury after hypotension. A bleeding tendency and the cause of tissue injury are separate questions.
Reasoning steps for option A
What condition can cause high-shear multimer loss?
Severe aortic stenosis can impair primary hemostasis through multimer cleavage.
Would that explain the demonstrated bowel injury?
A hemostatic defect does not itself explain the acute left-colon injury after hypotension.
Why does a shear-related bleeding tendency not explain the descending-colon CT finding?
A multimer defect can impair hemostasis but does not account for painful segmental bowel injury following dialysis-associated hypotension.
B. Oozing from an ulcerated colorectal tumor (Why this does not fit)
A tumor may cause chronic occult loss or intermittent overt bleeding. The episode follows prolonged hypotension and has new segmental inflammatory changes. Integrate the precipitating event with the tissue pattern.
Reasoning steps for option B
How can colorectal cancer cause anemia?
A tumor may cause chronic occult loss or intermittent overt bleeding.
What argues for an acute low-flow process here?
The episode follows prolonged hypotension and has new segmental inflammatory changes.
How does the post-dialysis sequence favor hypoperfusion over tumor bleeding?
Hypotension followed by pain, bloody diarrhea and segmental descending-colon thickening supports an acute low-flow injury rather than tumor oozing.
C. Transient hypoperfusion with colonic mucosal injury (Best answer)
Hypotension is followed by pain and then bloody diarrhea. The abnormality is segmental and left-sided, separate from the old cecal finding. Low-flow ischemic colitis best accounts for the painful segmental injury.
Reasoning steps for option C
What is the important temporal sequence?
Hypotension is followed by pain and then bloody diarrhea.
Where does imaging place the new injury?
The abnormality is segmental and left-sided, separate from the old cecal finding.
What explanation integrates timing and distribution?
Low-flow ischemic colitis best accounts for the painful segmental injury.
Why does the old cecal lesion not outweigh the new left-sided injury?
The timing after hypotension and the painful segmental descending-colon abnormality support ischemic colitis, anatomically separate from the old cecal lesion.
D. Intermittent hemorrhage from the old cecal ectasia (Why this does not fit)
A cecal angioectasia can cause intermittent painless bleeding. Post-hypotension pain and segmental descending-colon injury are not explained by an old dry cecal tuft. Do not let a known lesion override the present syndrome.
Reasoning steps for option D
How can angioectasia present?
A cecal angioectasia can cause intermittent painless bleeding.
Which findings require an additional explanation?
Post-hypotension pain and segmental descending-colon injury are not explained by an old dry cecal tuft.
Which location and symptom pattern argue against the old cecal ectasia?
Pain after hypotension and injury in the descending colon are not explained by intermittent painless bleeding from a cecal ectasia.
E. Arterial rupture at a sigmoid diverticulum (Why this does not fit)
An injured diverticular artery can cause abrupt painless hematochezia. Pain preceding blood and segmental wall injury after hypotension favor ischemic colitis. The sequence of pain and bleeding helps distinguish competing sources.
Reasoning steps for option E
What bleeding pattern can diverticula produce?
An injured diverticular artery can cause abrupt painless hematochezia.
What does this patient have beyond hematochezia?
Pain preceding blood and segmental wall injury after hypotension favor ischemic colitis.
Why does pain preceding blood argue against diverticular arterial rupture?
Diverticular hemorrhage is typically painless, whereas the pain-before-blood sequence with post-hypotension segmental injury supports ischemic colitis.
Takeaway: New pain and segmental injury can redirect the diagnosis away from a known angioectasia.
A. Prophylactic argon plasma coagulation (Why this does not fit)
APC can treat an accessible angioectasia responsible for clinically important bleeding. This patient has no bleeding, anemia or iron depletion. The ability to ablate a lesion is not itself a reason to do so.
Reasoning steps for option A
When can APC offer benefit?
APC can treat an accessible angioectasia responsible for clinically important bleeding.
Is that indication present?
This patient has no bleeding, anemia or iron depletion.
Why does technical suitability for APC not justify treating this patch?
A small accessible vascular patch without bleeding, anemia or iron depletion provides no prophylactic ablation indication.
B. Catheter angiography with embolization (Why this does not fit)
Angiographic embolization can control localized active major bleeding when endoscopic control is inadequate or impractical. There is no ongoing hemorrhage requiring arterial localization and control. Reserve invasive hemostasis for a justified bleeding indication.
Reasoning steps for option B
When is embolization useful?
Angiographic embolization can control localized active major bleeding when endoscopic control is inadequate or impractical.
What target is absent here?
There is no ongoing hemorrhage requiring arterial localization and control.
Why is arterial embolization disproportionate to this screening finding?
There is no active hemorrhage requiring arterial localization or control in this asymptomatic patient.
C. Observation without prophylactic lesion treatment (Best answer)
The history and supplied laboratory results do not show bleeding or iron deficiency. Screening colonoscopy identifies an incidental vascular lesion but does not establish a treatment indication. Observation avoids exposing an asymptomatic patient to unnecessary intervention.
Reasoning steps for option C
Is there evidence of blood loss or depleted iron?
The history and supplied laboratory results do not show bleeding or iron deficiency.
What is the significance of the endoscopic appearance alone?
Screening colonoscopy identifies an incidental vascular lesion but does not establish a treatment indication.
How should benefit and burden be balanced?
Observation avoids exposing an asymptomatic patient to unnecessary intervention.
How do hemoglobin 14.4 g/dL and ferritin 92 ng/mL support observation?
Neither anemia nor iron depletion is demonstrated, and the dry incidental patch has no clinical bleeding indication for treatment.
D. Elective right hemicolectomy (Why this does not fit)
Selected localized refractory bleeding may require surgical assessment. He has never bled and has a small incidental lesion. Surgical burden is disproportionate to an asymptomatic vascular finding.
Reasoning steps for option D
What would justify considering bowel resection?
Selected localized refractory bleeding may require surgical assessment.
Does this patient have refractory bleeding?
He has never bled and has a small incidental lesion.
What makes right hemicolectomy unjustified for this 4-mm lesion?
The lesion is incidental in a patient who has never bled, not a localized source of refractory bleeding warranting surgical assessment.
E. Long-acting octreotide therapy (Why this does not fit)
Trial evidence concerns selected patients with substantial recurrent bleeding support needs. The patient has no blood loss and has not needed iron or transfusions. Do not extrapolate refractory-disease treatment to incidental findings.
Reasoning steps for option E
Which population supports systemic octreotide treatment?
Trial evidence concerns selected patients with substantial recurrent bleeding support needs.
Does this screening finding resemble that population?
The patient has no blood loss and has not needed iron or transfusions.
Why does evidence for octreotide in refractory bleeding not apply here?
He has no blood loss, iron requirement or transfusion burden, unlike patients treated for substantial recurrent bleeding.
Takeaway: An incidental nonbleeding angioectasia generally needs no prophylactic ablation.
A. Endoscopic hemostasis with iron replacement (Best answer)
The accessible cecal lesion is actively oozing in a patient with compatible bleeding. Markedly depleted iron stores need replacement in addition to control of further loss. Endoscopic hemostasis addresses the lesion while iron replacement treats the deficit.
Reasoning steps for option A
What identifies the source?
The accessible cecal lesion is actively oozing in a patient with compatible bleeding.
What does the low ferritin add?
Markedly depleted iron stores need replacement in addition to control of further loss.
Which treatment combination matches both findings?
Endoscopic hemostasis addresses the lesion while iron replacement treats the deficit.
Why are both hemostasis and iron replacement needed with ferritin 6 ng/mL?
Endoscopic treatment controls the accessible oozing cecal source, but the markedly depleted iron stores still require replacement.
B. Segmental colectomy with iron replacement (Why this does not fit)
Surgery may be considered for accurately localized refractory bleeding. An accessible lesion has not yet undergone an endoscopic treatment attempt. Do not bypass a suitable less invasive source-directed treatment.
Reasoning steps for option B
When can resection enter the discussion?
Surgery may be considered for accurately localized refractory bleeding.
What earlier treatment opportunity is available?
An accessible lesion has not yet undergone an endoscopic treatment attempt.
Why should endoscopic treatment precede consideration of colectomy?
The patient is stable and the bleeding cecal lesion is accessible but has not yet had an endoscopic hemostasis attempt.
C. Catheter embolization with iron replacement (Why this does not fit)
Catheter embolization can control localized major bleeding not adequately managed endoscopically. The patient is stable and the oozing lesion is directly accessible for endoscopic treatment. Match the invasiveness of hemostasis to severity and access.
Reasoning steps for option C
When might embolization be appropriate?
Catheter embolization can control localized major bleeding not adequately managed endoscopically.
Why is it not the first source-directed choice here?
The patient is stable and the oozing lesion is directly accessible for endoscopic treatment.
How do stability and endoscopic access weigh against first-line embolization?
The oozing lesion can be treated directly during prepared colonoscopy, without initially escalating to catheter-based hemostasis.
D. Parenteral iron without endoscopic hemostasis (Why this does not fit)
Parenteral iron can replenish iron in selected patients with deficiency. The examination demonstrates an actively oozing accessible lesion. Replacement alone does not treat an observed bleeding source.
Reasoning steps for option D
What problem does intravenous iron address?
Parenteral iron can replenish iron in selected patients with deficiency.
What source problem persists in this case?
The examination demonstrates an actively oozing accessible lesion.
What would remain untreated if only intravenous iron were given?
Iron would replenish the deficit while leaving the directly observed, accessible oozing cecal lesion without hemostasis.
E. Endoscopic hemostasis without iron replacement (Why this does not fit)
Endoscopic hemostasis can reduce further bleeding from the treated vascular lesion. Ferritin is markedly low, and stopping loss does not replenish iron stores. Source control and iron recovery are complementary.
Reasoning steps for option E
What can endoscopic hemostasis achieve?
Endoscopic hemostasis can reduce further bleeding from the treated vascular lesion.
Which measured deficit would remain?
Ferritin is markedly low, and stopping loss does not replenish iron stores.
Why does controlling cecal oozing not eliminate the need for iron?
Ferritin of 6 ng/mL indicates depleted stores; stopping further loss does not restore iron already lost.
Takeaway: Stopping blood loss does not replenish iron stores.
A. CT enterography after oral contrast preparation (Why this does not fit)
CT enterography evaluates small-bowel structure, including suspected masses or stenosis. The immediate target is active luminal hemorrhage, not a structural survey for a chronic small-bowel process. Angiographic and enterographic CT protocols answer different questions.
Reasoning steps for option A
What is CT enterography useful for?
CT enterography evaluates small-bowel structure, including suspected masses or stenosis.
What needs localization now?
The immediate target is active luminal hemorrhage, not a structural survey for a chronic small-bowel process.
Why is an enterographic structural survey not the appropriate urgent CT protocol?
Continuing large-volume hematochezia requires localization of active extravasation, not a delayed small-bowel structural assessment.
B. Tagged red-cell imaging with delayed surveillance (Why this does not fit)
Tagged red-cell imaging can detect bleeding over a longer observation interval. Rapid precise localization of ongoing major bleeding is needed to guide intervention. Select the acute pathway rather than a slower surveillance strategy.
Reasoning steps for option B
What can tagged red-cell imaging detect?
Tagged red-cell imaging can detect bleeding over a longer observation interval.
What advantage is needed in this situation?
Rapid precise localization of ongoing major bleeding is needed to guide intervention.
Why is prolonged tagged-cell surveillance less suitable than rapid localization here?
The continuing major hemorrhage requires precise localization promptly enough to guide intervention rather than a slower observation strategy.
C. Nonurgent colonoscopy after routine preparation (Why this does not fit)
Colonoscopy diagnoses and can treat sources in stable patients when preparation is feasible. Ongoing major blood passage prevents timely adequate preparation. Do not apply the nonurgent inpatient pathway to uncontrolled major bleeding.
Reasoning steps for option C
When is prepared colonoscopy valuable?
Colonoscopy diagnoses and can treat sources in stable patients when preparation is feasible.
What practical condition is missing?
Ongoing major blood passage prevents timely adequate preparation.
Why should routine preparation not delay acute bleeding localization?
Ongoing major blood passage prevents timely adequate preparation, so the nonurgent colonoscopy pathway does not meet the current need.
D. Capsule endoscopy after an overnight fast (Why this does not fit)
Capsule endoscopy can identify mucosal lesions when small-bowel assessment is indicated. The patient needs rapid localization of continuing major hemorrhage rather than a delayed mucosal survey. The bleeding state determines which test has immediate value.
Reasoning steps for option D
What can capsule endoscopy examine?
Capsule endoscopy can identify mucosal lesions when small-bowel assessment is indicated.
What urgent need does it not meet as well here?
The patient needs rapid localization of continuing major hemorrhage rather than a delayed mucosal survey.
Why is a capsule mucosal survey poorly timed during this hemorrhage?
Continuing major blood loss calls for rapid localization linked to intervention, rather than delayed inspection after an overnight fast.
E. CT angiography during the ongoing hemorrhage (Best answer)
Ongoing major hematochezia requires rapid localization after initial resuscitation. Continuing blood passage makes timely adequate preparation impractical. CTA can identify an active leak and guide prompt angiographic management.
Reasoning steps for option E
What does the current bleeding pattern require?
Ongoing major hematochezia requires rapid localization after initial resuscitation.
Why is routine prepared colonoscopy less suitable at this moment?
Continuing blood passage makes timely adequate preparation impractical.
Which test can connect localization to intervention?
CTA can identify an active leak and guide prompt angiographic management.
What makes CTA useful now rather than during a later quiet interval?
The hemorrhage is ongoing, allowing CTA to detect an active leak and guide prompt angiographic management when bowel preparation is impractical.
Takeaway: Ongoing significant bleeding and a quiet interval require different localization strategies.
A. Repeat hemoglobin before starting resuscitation (Why this does not fit)
Repeated measurements help assess the evolving blood-loss picture. The patient already has shock findings despite the initial hemoglobin concentration. Laboratory reassessment should accompany, not delay, emergency care.
Reasoning steps for option A
Why is serial hemoglobin useful?
Repeated measurements help assess the evolving blood-loss picture.
Can the first value override the bedside state?
The patient already has shock findings despite the initial hemoglobin concentration.
Why must repeat hemoglobin not be a prerequisite for resuscitation at 78/46 mm Hg?
Hypotension, tachycardia and confusion already indicate shock; serial hemoglobin should accompany emergency care rather than delay it.
B. Begin hemorrhage resuscitation while arranging urgent source control (Best answer)
Hypotension, tachycardia and poor mentation indicate threatened perfusion. An early hemoglobin concentration can underestimate the magnitude of a recent hemorrhage. Resuscitation and urgent source assessment must not wait for a larger laboratory decline.
Reasoning steps for option B
What do the examination findings establish?
Hypotension, tachycardia and poor mentation indicate threatened perfusion.
Does the early hemoglobin exclude severe acute loss?
An early hemoglobin concentration can underestimate the magnitude of a recent hemorrhage.
Which priority follows from that mismatch?
Resuscitation and urgent source assessment must not wait for a larger laboratory decline.
Why does hemoglobin 12.0 g/dL not justify waiting after these bloody stools?
The measurement is early after major loss and can underestimate its severity, while the bedside findings already show threatened perfusion.
C. Observe because the prior lesion was ablated (Why this does not fit)
Prior ablation can establish hemostasis at a treated site at that time. Large-volume bleeding with shock demonstrates that the patient now needs urgent treatment. Prior local control does not exclude a new hemorrhage.
Reasoning steps for option C
What does successful ablation establish?
Prior ablation can establish hemostasis at a treated site at that time.
What does the current episode show?
Large-volume bleeding with shock demonstrates that the patient now needs urgent treatment.
Why does prior cecal ablation not justify observing the present episode?
Prior local hemostasis does not exclude new hemorrhage, and current large bloody stools with shock require urgent treatment.
D. Start oral iron and reassess blood pressure later (Why this does not fit)
Oral iron addresses iron depletion during recovery from blood loss. Shock requires restoration of perfusion, not delayed correction of iron stores. Separate emergency oxygen-delivery needs from longer-term iron recovery.
Reasoning steps for option D
What does iron replacement treat?
Oral iron addresses iron depletion during recovery from blood loss.
What immediate problem dominates here?
Shock requires restoration of perfusion, not delayed correction of iron stores.
Why is oral iron inadequate for the immediate perfusion problem?
Iron replenishes stores during recovery but cannot replace immediate resuscitation for hypotension, confusion and cool extremities.
E. Perform capsule endoscopy before vascular access (Why this does not fit)
Recurrent bleeding can arise from additional gastrointestinal lesions. Threatened perfusion requires immediate vascular access and resuscitation. A known diagnosis never reverses emergency priorities.
Reasoning steps for option E
Why might a previous angioectasia prompt bowel evaluation?
Recurrent bleeding can arise from additional gastrointestinal lesions.
What must precede a nonresuscitative investigation?
Threatened perfusion requires immediate vascular access and resuscitation.
Why must vascular access precede capsule investigation despite known angioectasia?
The patient has shock requiring immediate access and resuscitation; identifying further mucosal lesions cannot take priority over restoring perfusion.
Takeaway: In acute hemorrhage, act on perfusion and ongoing loss rather than a single early hemoglobin.
A. Proceed with prepared colonoscopic source evaluation (Best answer)
CTA found no active contrast leak during the examined quiet interval. Repeated bleeding and iron-deficiency anemia still require source evaluation. A current adequate colon examination is needed and can also provide therapy.
Reasoning steps for option A
What did the negative CTA measure?
CTA found no active contrast leak during the examined quiet interval.
What problem remains unresolved?
Repeated bleeding and iron-deficiency anemia still require source evaluation.
Which assessment is currently missing?
A current adequate colon examination is needed and can also provide therapy.
Why is colonoscopy still indicated after a CTA obtained once stools cleared?
The quiet-interval CTA found no active leak but does not resolve recurrent bleeding and iron deficiency, especially without adequate colon evaluation for six years.
B. Schedule empiric embolization of the right colic artery (Why this does not fit)
Angioectasias commonly occur in the right colon. No source has been localized by CTA or a current colonoscopy. A common location does not justify an empiric arterial intervention.
Reasoning steps for option B
Why does a right-sided source enter the differential?
Angioectasias commonly occur in the right colon.
Has this patient had a target localized there?
No source has been localized by CTA or a current colonoscopy.
Why does the usual right-colon location not authorize right colic embolization?
Neither CTA nor current colonoscopy has localized a right-sided target, so common lesion distribution cannot justify empiric arterial treatment.
C. Repeat CTA routinely while stools remain clear (Why this does not fit)
CTA is especially useful during ongoing clinically significant bleeding. There is no new active major episode, and the colon evaluation remains incomplete. Address the missing investigation rather than repeat the same quiet-interval test.
Reasoning steps for option C
When is CTA especially informative?
CTA is especially useful during ongoing clinically significant bleeding.
What makes immediate repetition less informative here?
There is no new active major episode, and the colon evaluation remains incomplete.
Why address the missing colon examination instead of repeating quiet-interval CTA?
There is no new major active episode to improve CTA yield, while a current adequate colon examination remains necessary.
D. Give octreotide without further source investigation (Why this does not fit)
Octreotide can be considered for selected refractory angiodysplasia-related bleeding. The current bleeding source has not been adequately evaluated. Refractory-disease treatment should not replace initial source assessment.
Reasoning steps for option D
When can octreotide enter treatment?
Octreotide can be considered for selected refractory angiodysplasia-related bleeding.
What diagnosis remains unestablished?
The current bleeding source has not been adequately evaluated.
Why is octreotide premature before the current source is established?
A negative quiet-interval CTA does not diagnose refractory angiodysplasia; the recurrent bleeding first needs adequate source evaluation.
E. Conclude that a vascular lesion has been excluded (Why this does not fit)
CTA can demonstrate an active luminal leak. However, a lesion may not be bleeding at the instant of imaging. A negative time-dependent test is not proof that the source never bleeds.
Reasoning steps for option E
What does a positive active-bleeding CTA provide?
It can demonstrate an active luminal leak.
Does a quiet-interval negative study exclude intermittent bleeding?
No; the lesion may not be bleeding at the instant of imaging.
What limitation of the CTA timing prevents exclusion of a vascular lesion?
Imaging occurred after visible bleeding stopped, so an intermittently bleeding lesion could have produced no extravasation at that moment.
Takeaway: A quiet-interval negative CTA leaves intermittent bleeding on the differential.
A. Observation without additional investigation (Why this does not fit)
Observation can be appropriate after adequate negative evaluation when bleeding has resolved and clinical circumstances support it. Recurrent overt bleeding and iron deficiency persist without a completed small-bowel assessment. Persistent loss warrants further evaluation rather than unconditional reassurance.
Reasoning steps for option A
When might conservative follow-up be reasonable?
Observation can be appropriate after adequate negative evaluation when bleeding has resolved and clinical circumstances support it.
What remains active in this history?
Recurrent overt bleeding and iron deficiency persist without a completed small-bowel assessment.
Why is reassurance insufficient after these negative upper and lower studies?
Recurrent melena and iron deficiency persist, and the small bowel has not yet been adequately assessed.
B. Emergency catheter angiography during the quiet interval (Why this does not fit)
Catheter angiography can localize and treat significant active bleeding in an acute setting. The patient is stable without continuing major hemorrhage, favoring mucosal small-bowel investigation. Reserve the emergency vascular pathway for the appropriate bleeding state.
Reasoning steps for option B
When is catheter angiography most useful?
Catheter angiography can localize and treat significant active bleeding in an acute setting.
What is the current physiologic state?
The patient is stable without continuing major hemorrhage, favoring mucosal small-bowel investigation.
Why does this stable presentation not favor emergency catheter angiography?
There is no continuing major hemorrhage requiring an acute vascular intervention; the remaining diagnostic need is small-bowel mucosal evaluation.
C. Right hemicolectomy for presumed cecal angioectasia (Why this does not fit)
The cecum is a common site of colonic angioectasia. However, this high-quality colonoscopy did not identify a cecal lesion. An epidemiologic preference is not surgical localization.
Reasoning steps for option C
Why might the cecum be considered?
It is a common site of colonic angioectasia.
Has a cecal source been demonstrated?
No; the colonoscopy was high quality and did not identify one.
Why is the cecum's usual association with angioectasia insufficient for resection?
A recent high-quality colonoscopy found no cecal source, so a presumed common location is not surgical localization.
D. Routine repetition of both recent endoscopic examinations (Why this does not fit)
Repeating an endoscopic examination can be appropriate if the previous study was inadequate or the current presentation indicates a missed accessible source. Both recent examinations were high quality without a source. Do not routinely repeat adequate studies before indicated small-bowel evaluation.
Reasoning steps for option D
When is repeat conventional endoscopy useful?
Repeating an endoscopic examination can be appropriate if the previous study was inadequate or the current presentation indicates a missed accessible source.
What does the supplied quality information show?
Both recent examinations were high quality without a source.
Why should the recent adequate scopes not be routinely repeated before small-bowel testing?
Neither examination had a supplied quality limitation or evidence requiring reassessment, while persistent bleeding leaves the small bowel unexplored.
E. Early small-bowel capsule endoscopy (Best answer)
Much of the small-bowel mucosa lies beyond the examinations already completed. He has no supplied evidence of obstruction and has a recent overt episode that can improve diagnostic yield. Early capsule endoscopy is a first-line small-bowel mucosal investigation in this setting.
Reasoning steps for option E
What territory remains incompletely assessed?
Much of the small-bowel mucosa lies beyond the examinations already completed.
What safety and timing information matters?
He has no supplied evidence of obstruction and has a recent overt episode that can improve diagnostic yield.
Which investigation fits these conditions?
Early capsule endoscopy is a first-line small-bowel mucosal investigation in this setting.
How do the negative scopes, recent melena and lack of obstruction support early capsule testing?
The small bowel remains unexamined, the recent overt episode can improve yield, and no supplied obstruction features require a different initial sequence.
Takeaway: After adequate negative upper and lower studies, investigate the small bowel when bleeding persists.
A. Exploratory surgery without enteroscopic assessment (Why this does not fit)
Selected refractory or otherwise unmanageable bleeding may require resection after localization. The enteroscopy team can reach the identified lesions. Do not bypass a feasible endoscopic treatment pathway without a reason.
Reasoning steps for option A
When can surgery be necessary?
Selected refractory or otherwise unmanageable bleeding may require resection after localization.
What suitable treatment opportunity has not been used?
The enteroscopy team can reach the identified lesions.
Why should exploratory surgery not precede enteroscopy for these jejunal lesions?
The identified lesions are reachable by the enteroscopy team, providing a feasible confirmation and treatment pathway before surgical escalation.
B. Device-assisted enteroscopy directed to the capsule findings (Best answer)
Capsule endoscopy has localized a likely bleeding source in the proximal jejunum, but the capsule cannot deliver hemostatic therapy. Targeted device-assisted enteroscopy can confirm and treat accessible small-bowel lesions.
Reasoning steps for option B
What has the capsule contributed?
It has localized a likely bleeding source in the proximal jejunum.
What can the capsule not provide?
It cannot deliver hemostatic therapy.
Which procedure supplies the missing capability?
Targeted device-assisted enteroscopy can confirm and treat accessible small-bowel lesions.
What capability must follow capsule localization of the bleeding jejunal ectasia?
Capsule imaging identifies the target but cannot treat it; directed device-assisted enteroscopy can confirm the lesions and deliver hemostasis.
C. Catheter angiography without current major bleeding (Why this does not fit)
Catheter angiography may permit rapid arterial localization and embolization. She is stable with localized mucosal lesions judged reachable for enteroscopic treatment. Choose the procedure that matches both the target and the current state.
Reasoning steps for option C
What does angiography offer during significant active bleeding?
Catheter angiography may permit rapid arterial localization and embolization.
Why is another approach more directly matched here?
She is stable with localized mucosal lesions judged reachable for enteroscopic treatment.
Why does stable, reachable jejunal disease favor enteroscopy over catheter angiography?
The target is a localized mucosal lesion accessible to endoscopic treatment, without current major hemorrhage demanding rapid arterial intervention.
D. Routine colonoscopy focused on the cecum (Why this does not fit)
Colonoscopy can treat accessible colonic sources. Capsule endoscopy localized the likely bleeding source to the proximal jejunum, beyond routine colonoscopic reach. Anatomical access matters more than the most familiar location.
Reasoning steps for option D
What can colonoscopy treat?
Colonoscopy can treat accessible colonic sources.
Where is the demonstrated candidate source?
Capsule endoscopy localized the likely bleeding source to the proximal jejunum, beyond routine colonoscopic reach.
Why would a cecum-focused colonoscopy miss the identified treatment target?
The lesions with fresh blood lie in the proximal jejunum, beyond routine colonoscopic reach.
E. A second capsule study without therapeutic planning (Why this does not fit)
A repeat capsule examination may help if an earlier examination was nondiagnostic and bleeding persists. The capsule has identified reachable jejunal lesions with fresh blood. Once localization is adequate, select a modality that can supply treatment.
Reasoning steps for option E
When can repeating capsule testing be useful?
A repeat capsule examination may help if an earlier examination was nondiagnostic and bleeding persists.
What is already known here?
The capsule has identified reachable jejunal lesions with fresh blood.
Why is another capsule study not the missing step after this diagnostic study?
Reachable jejunal lesions have already been localized; the remaining need is therapeutic access, which another capsule cannot provide.
Takeaway: Capsule finds mucosal lesions; enteroscopy can confirm and treat selected targets.
A. Repeat routine colonoscopy before assessing the narrowing (Why this does not fit)
Repeat colonoscopy can help after inadequate visualization or evidence of a missed colonic source. The previous colonoscopy was adequate, and the concern is a possible ileal narrowing. Repeating an adequate colonic study does not establish capsule safety.
Reasoning steps for option A
When might repeat colonoscopy help?
Repeat colonoscopy can help after inadequate visualization or evidence of a missed colonic source.
What is the unresolved safety issue?
The previous colonoscopy was adequate, and the concern is a possible ileal narrowing.
Why would repeating the adequate colonoscopy not establish capsule safety?
The unresolved retention risk is a possible ileal narrowing with distension and vomiting, not an inadequately examined colon.
B. Start systemic treatment for presumed angioectasia (Why this does not fit)
Systemic treatment is considered for selected refractory bleeding with a sufficiently established source. The small-bowel lesion is uncharacterized and the possible stenosis still needs assessment. Do not replace anatomical evaluation with an assumed vascular diagnosis.
Reasoning steps for option B
What supports systemic treatment of angioectasia?
Systemic treatment is considered for selected refractory bleeding with a sufficiently established source.
What diagnosis and risk remain unresolved?
The small-bowel lesion is uncharacterized and the possible stenosis still needs assessment.
Why is presumed angioectasia treatment not a substitute for evaluating the ileum?
The small-bowel source is uncharacterized, and the prior narrowing with obstructive symptoms needs anatomical assessment rather than an assumed vascular diagnosis.
C. Use CT angiography during the symptom-free interval (Why this does not fit)
CTA can rapidly identify active luminal hemorrhage. A suspected structural stenosis, not an ongoing major leak, needs evaluation. Match the CT protocol to the structural or bleeding question.
Reasoning steps for option C
What is angiographic CT optimized to detect?
CTA can rapidly identify active luminal hemorrhage.
What needs assessment before capsule ingestion?
A suspected structural stenosis, not an ongoing major leak, needs evaluation.
Why does suspected ileal stenosis call for enterographic rather than angiographic CT?
The immediate question is structural narrowing and capsule retention risk, not localization of an active major luminal leak.
D. Proceed directly to capsule endoscopy (Why this does not fit)
Capsule endoscopy is a first-line small-bowel test when clinically indicated without a contraindication. Symptoms and a prior focal narrowing raise an obstruction and retention concern. The usual first-line test still requires a safety assessment.
Reasoning steps for option D
When is direct capsule examination reasonable?
Capsule endoscopy is a first-line small-bowel test when clinically indicated without a contraindication.
What risk information is present here?
Symptoms and a prior focal narrowing raise an obstruction and retention concern.
Why is passing stool insufficient to justify immediate diagnostic capsule ingestion?
Intermittent vomiting, distension and a previously described ileal narrowing still raise concern for retention despite current stability and stool passage.
E. Assess the suspected narrowing with CT enterography (Best answer)
Persistent iron deficiency remains unexplained after adequate upper and lower examinations. Obstructive symptoms and a known possible ileal narrowing raise concern for capsule retention. CT enterography can assess the suspected structural narrowing before a diagnostic capsule is swallowed.
Reasoning steps for option E
Why is small-bowel evaluation reasonable?
Persistent iron deficiency remains unexplained after adequate upper and lower examinations.
What changes the safety of a capsule-first plan?
Obstructive symptoms and a known possible ileal narrowing raise concern for capsule retention.
Which investigation addresses that constraint?
CT enterography can assess the suspected structural narrowing before a diagnostic capsule is swallowed.
How does the radiation-associated ileal narrowing change the capsule-first sequence?
The possible stenosis and obstructive symptoms warrant structural assessment with CT enterography before a diagnostic capsule is swallowed.
Takeaway: Suspected stenosis changes the sequence before capsule endoscopy.
A. Repeat colonoscopy with adequate bowel preparation (Best answer)
The right colon was poorly visualized and the cecum was not reached. Both vascular lesions and other important causes of blood loss may lie in the unexamined colon. A properly prepared complete colonoscopy addresses the inadequacy before treating the study as negative.
Reasoning steps for option A
Was the colon adequately excluded as a source?
The right colon was poorly visualized and the cecum was not reached.
Why does that limitation matter for this presentation?
Both vascular lesions and other important causes of blood loss may lie in the unexamined colon.
What corrects the actual gap?
A properly prepared complete colonoscopy addresses the inadequacy before treating the study as negative.
Why must the right colon be reexamined before calling this evaluation negative?
Solid stool obscured the ascending colon and the cecum was not reached, leaving possible vascular or other bleeding lesions unevaluated.
B. Empiric cecal ablation without a complete examination (Why this does not fit)
A suitable vascular target with a treatment indication needs to be identified. The cecum has not been reached, so no lesion or culprit has been established there. A commonly affected region is not the same as a demonstrated target.
Reasoning steps for option B
What needs to be identified before focal ablation?
A suitable vascular target with a treatment indication needs to be identified.
Has the cecum been examined?
The cecum has not been reached, so no lesion or culprit has been established there.
Why is empiric cecal ablation unsupported when the cecum was not reached?
No cecal lesion has been visualized or identified as responsible, so there is no demonstrated focal target to ablate.
C. Capsule endoscopy based on two negative scopes (Why this does not fit)
Capsule endoscopy is supported after appropriate assessment of accessible sources when small-bowel evaluation is indicated. The colon examination was incomplete and poorly prepared. A technically incomplete examination is not an adequate negative study.
Reasoning steps for option C
When is capsule-first small-bowel evaluation supported?
Capsule endoscopy is supported after appropriate assessment of accessible sources when small-bowel evaluation is indicated.
Were both examinations genuinely negative and adequate?
The colon examination was incomplete and poorly prepared.
Why do these two procedures not qualify as adequate negative upper and lower studies?
The upper study was complete, but poor preparation and failure to reach the cecum leave the colon incompletely assessed before small-bowel testing.
D. Repeat upper endoscopy before colon reassessment (Why this does not fit)
Repeat upper endoscopy can help when the first was inadequate or new evidence suggests a missed upper source. The colonoscopy, not the complete normal upper examination, has the supplied limitation. Repeat the test with the demonstrated deficiency.
Reasoning steps for option D
When can a second upper examination be useful?
Repeat upper endoscopy can help when the first was inadequate or new evidence suggests a missed upper source.
Which documented examination is inadequate here?
The colonoscopy, not the complete normal upper examination, has the supplied limitation.
Why repeat the colonoscopy rather than the complete normal upper endoscopy?
The documented deficiency is obscured and unexamined right colon, not inadequate upper-tract visualization.
E. Routine observation without further source assessment (Why this does not fit)
Observation may be reasonable after adequate evaluation when bleeding and anemia are not ongoing concerns. The patient has iron deficiency and an important unexamined colonic region. Complete the indicated source assessment before offering reassurance.
Reasoning steps for option E
When is observation appropriate after negative investigation?
Observation may be reasonable after adequate evaluation when bleeding and anemia are not ongoing concerns.
Why is that conclusion premature here?
The patient has iron deficiency and an important unexamined colonic region.
Why is observation premature with persistent iron deficiency and an unexamined cecum?
Important potential colonic sources remain unevaluated, so a complete source assessment is needed before reassurance.
Takeaway: Read the procedure-quality report, not just the word negative.
A. Immediate colectomy without angiographic assessment (Why this does not fit)
Localized bleeding unmanageable by other means may require surgery. An immediately available team can access the localized bleeding branch for embolization. Use the appropriate source-directed option before escalating to resection when circumstances permit.
Reasoning steps for option A
When can surgery become necessary?
Localized bleeding unmanageable by other means may require surgery.
What less invasive available option matches the supplied target?
An immediately available team can access the localized bleeding branch for embolization.
Why attempt available targeted embolization before immediate colectomy?
CTA has localized an accessible bleeding branch and interventional radiology is immediately available, offering source-directed treatment before resection.
B. Long-acting octreotide as sole acute hemostasis (Why this does not fit)
Long-acting octreotide can reduce recurrent support needs in selected refractory patients over time. This patient has ongoing major hemorrhage with an immediately treatable localized source. Recurrence prevention does not substitute for urgent source control.
Reasoning steps for option B
What role can octreotide have?
Long-acting octreotide can reduce recurrent support needs in selected refractory patients over time.
What makes it insufficient as the sole next intervention?
This patient has ongoing major hemorrhage with an immediately treatable localized source.
Why cannot long-acting octreotide serve as sole hemostasis for this cecal leak?
It addresses recurrent bleeding burden over time, whereas ongoing major hemorrhage from a localized source requires urgent control.
C. Oral iron with interval hemoglobin monitoring (Why this does not fit)
Oral iron supports recovery of depleted iron stores. Major active bleeding continues despite an attempted endoscopic intervention. Replacement and monitoring cannot replace acute hemostasis.
Reasoning steps for option C
What does oral iron provide?
Oral iron supports recovery of depleted iron stores.
What problem requires immediate attention?
Major active bleeding continues despite an attempted endoscopic intervention.
Why are oral iron and interval monitoring insufficient after failed endoscopic control?
Major bleeding is still active on CTA; restoring iron stores and tracking hemoglobin do not stop the hemorrhage.
D. Capsule endoscopy to inspect the small bowel (Why this does not fit)
Capsule endoscopy can identify otherwise unrecognized small-bowel mucosal lesions. The current active bleeding target is localized to the cecum. Do not postpone control of an established active source for an unrelated survey.
Reasoning steps for option D
What question can capsule testing answer?
Capsule endoscopy can identify otherwise unrecognized small-bowel mucosal lesions.
What information is already available?
The current active bleeding target is localized to the cecum.
Why should capsule inspection not delay treatment of the CTA-localized cecal source?
The current bleeding target is already established in the cecum, so an unrelated small-bowel survey would postpone urgent source control.
E. Catheter angiography with targeted embolization (Best answer)
CTA demonstrates an active localized bleeding target. Endoscopic control has been unsuccessful during a major recurrent hemorrhage. Targeted angiographic embolization can provide source control, with attention to ischemic risk.
Reasoning steps for option E
What does the current CTA add?
CTA demonstrates an active localized bleeding target.
What has happened to the endoscopic pathway?
Endoscopic control has been unsuccessful during a major recurrent hemorrhage.
Which available treatment fits the target and urgency?
Targeted angiographic embolization can provide source control, with attention to ischemic risk.
Which combination makes targeted embolization appropriate in this recurrence?
Major bleeding persists after unsuccessful endoscopic therapy, CTA localizes an active cecal leak, and an available team can access the branch while considering ischemic risk.
Takeaway: A localized active leak can support embolization when endoscopic control fails.
A. The previous cecal lesion was accessible endoscopically (Why this does not fit)
A reachable responsible lesion may be amenable to less invasive treatment. Current studies identify bleeding throughout jejunal and ileal segments while the colon is quiet. Use the current source map rather than access to a previously treated lesion.
Reasoning steps for option A
Why does endoscopic access affect treatment selection?
A reachable responsible lesion may be amenable to less invasive treatment.
Is the former cecal lesion the currently demonstrated bleeding distribution?
Current studies identify bleeding throughout jejunal and ileal segments while the colon is quiet.
Why is access to the former cecal lesion not the decisive objection to right hemicolectomy?
The current bleeding sources are in long jejunal and ileal segments, so their location outside the resection is more relevant than access to a previously treated cecal lesion.
B. Rebleeding surveillance would still be needed after surgery (Why this does not fit)
Recurrent bleeding may arise even after successful local control. Known bleeding sources already lie outside the segment proposed for resection. Current source distribution is more direct evidence than a general need for follow-up.
Reasoning steps for option B
Why can follow-up remain useful after treatment?
Recurrent bleeding may arise even after successful local control.
What makes the proposed operation inadequate now, rather than merely uncertain later?
Known bleeding sources already lie outside the segment proposed for resection.
Why is the present source map a stronger objection than future surveillance needs?
Known small-bowel sources would remain immediately after right hemicolectomy, not merely pose an uncertain risk of later recurrence.
C. Perioperative red-cell support might still be required (Why this does not fit)
Anemia and procedural blood loss can require individualized perioperative management. The decisive limitation is leaving known bleeding lesions outside the resection. Perioperative support requirements and anatomical source control are distinct questions.
Reasoning steps for option C
Why might a patient need support around an operation?
Anemia and procedural blood loss can require individualized perioperative management.
Does a potential transfusion requirement define the source-control failure?
The decisive limitation is leaving known bleeding lesions outside the resection.
Why is perioperative transfusion need not the direct measure of this operation's failure?
Transfusion supports red-cell deficits, but the anatomical failure is leaving documented jejunal and ileal bleeding sources outside the resection.
D. Iron stores would still need replacement after surgery (Why this does not fit)
Prior blood loss may leave depleted stores even after effective source treatment. Iron recovery is a separate issue from whether the responsible lesions lie inside the resection. Distinguish correction of a deficit from control of the source.
Reasoning steps for option D
Why might depleted iron stores still need replacement after an otherwise effective resection?
Prior blood loss can leave stores depleted even after source control, so replacement need alone does not demonstrate anatomical failure of a resection.
Does that alone mean a localized operation cannot control its target?
Iron recovery is a separate issue from whether the responsible lesions lie inside the resection.
Why does persistent iron depletion not by itself determine whether surgery controls a source?
Iron can still need replacement after effective hemostasis; this operation fails anatomically because the small-bowel lesions lie outside its field.
E. The documented sources extend beyond the planned resection (Best answer)
The documented bleeding lesions are distributed through long jejunal and ileal segments, not confined to the right colon. A right hemicolectomy would leave extensive documented small-bowel lesions outside the resected segment. The operation cannot provide definitive source control for the demonstrated multifocal distribution.
Reasoning steps for option E
Where are the currently demonstrated bleeding sources?
The documented bleeding lesions are distributed through long jejunal and ileal segments, not confined to the right colon.
Would the proposed operation include those sources?
A right hemicolectomy would leave extensive documented small-bowel lesions outside the resected segment.
What limitation follows from that anatomical mismatch?
The operation cannot provide definitive source control for the demonstrated multifocal distribution.
How does right hemicolectomy compare with the documented jejunal and ileal distribution?
It removes the right colon, not the extensive documented small-bowel sources, so it cannot provide definitive control of that bleeding distribution.
Takeaway: The resection field must match the demonstrated bleeding distribution.
A. Platelet count repeated in citrate (Why this does not fit)
A citrate-tube platelet count can help assess suspected spurious thrombocytopenia from platelet clumping. The platelet count is normal; the concern is adhesive function rather than a falsely low count. A normal number of platelets does not prove normal primary hemostasis.
Reasoning steps for option A
When does a citrate-tube count help?
A citrate-tube platelet count can help assess suspected spurious thrombocytopenia from platelet clumping.
What count-related problem is supplied?
The platelet count is normal; the concern is adhesive function rather than a falsely low count.
Why would another normal platelet count not exclude the suspected valve-related defect?
Platelet number does not establish adhesive function or preservation of large von Willebrand multimers in severe aortic stenosis.
B. Factor V Leiden genotyping (Why this does not fit)
The factor V Leiden variant increases venous thrombotic risk through activated protein C resistance. It does not evaluate shear-related loss of large von Willebrand multimers. A thrombophilia test is not a test of this bleeding mechanism.
Reasoning steps for option B
What does factor V Leiden predispose to?
The factor V Leiden variant increases venous thrombotic risk through activated protein C resistance.
Does that explain the suspected valve-related mucosal bleeding?
It does not evaluate shear-related loss of large von Willebrand multimers.
Why does factor V Leiden testing not assess the suspected mucosal bleeding mechanism?
It evaluates a venous thrombophilia, not shear-related loss of large von Willebrand multimers associated with the stenotic valve.
C. Von Willebrand factor multimer analysis (Best answer)
Severe aortic stenosis can produce an acquired functional von Willebrand factor defect associated with angiodysplasia bleeding. Antigen quantity does not establish that the largest effective multimers are preserved. Multimer analysis assesses whether the high-molecular-weight forms are selectively depleted.
Reasoning steps for option C
What association links the valve and intestinal bleeding?
Severe aortic stenosis can produce an acquired functional von Willebrand factor defect associated with angiodysplasia bleeding.
Why does a normal antigen result not settle the question?
Antigen quantity does not establish that the largest effective multimers are preserved.
What test addresses that structural property?
Multimer analysis assesses whether the high-molecular-weight forms are selectively depleted.
Why seek multimer analysis despite a normal von Willebrand antigen concentration?
Antigen measures quantity but can remain normal despite selective depletion of the largest effective multimers in severe aortic stenosis.
D. Serum vitamin B12 measurement (Why this does not fit)
Vitamin B12 deficiency can cause ineffective blood-cell production and cytopenias. Recurrent vascular bleeding accompanies severe aortic stenosis without supplied cytopenias. Investigate the demonstrated clinical association instead of an unrelated anemia pathway.
Reasoning steps for option D
What hematologic problem can vitamin B12 deficiency cause?
Vitamin B12 deficiency can cause ineffective blood-cell production and cytopenias.
What relationship requires explanation here?
Recurrent vascular bleeding accompanies severe aortic stenosis without supplied cytopenias.
Why is vitamin B12 measurement less direct than testing von Willebrand multimer structure?
The supplied association is severe aortic stenosis with recurrent vascular-ectasia bleeding, not a B12-related cytopenic presentation.
E. Factor VII activity measurement (Why this does not fit)
Reduced factor VII activity can impair the extrinsic coagulation pathway and prolong prothrombin time. Severe valve stenosis with vascular-ectasia bleeding suggests a shear-related von Willebrand factor abnormality despite a normal prothrombin time. Choose the test for the proposed hemostatic process.
Reasoning steps for option E
What would reduced factor VII activity affect?
Reduced factor VII activity can impair the extrinsic coagulation pathway and prolong prothrombin time.
What is the more direct suspected link here?
Severe valve stenosis with vascular-ectasia bleeding suggests a shear-related von Willebrand factor abnormality despite a normal prothrombin time.
Why is factor VII activity not the most direct test of this valve-associated bleeding?
Normal prothrombin time and the valve-ectasia association direct attention toward a shear-related adhesive defect rather than an extrinsic-pathway factor deficiency.
Takeaway: Normal von Willebrand factor antigen does not exclude loss of its largest multimers.
A. Reduced coagulation-factor activity with intact primary hemostasis (Why this does not fit)
A coagulation-factor deficiency can impair fibrin formation through the coagulation pathways. The low collagen-binding activity identifies impaired adhesive function, while prothrombin time is normal. Use the abnormal measured function rather than assuming a different pathway.
Reasoning steps for option A
What can a coagulation-factor defect disrupt?
A coagulation-factor deficiency can impair fibrin formation through the coagulation pathways.
What evidence directly concerns primary hemostasis here?
The low collagen-binding activity identifies impaired adhesive function, while prothrombin time is normal.
Why does collagen-binding activity of 24% contradict intact primary hemostasis?
It directly demonstrates impaired von Willebrand adhesive function, while the normal prothrombin time does not support substituting a coagulation-pathway explanation.
B. Reduced protein quantity with preserved adhesive function (Why this does not fit)
A low antigen result would support reduced measured von Willebrand factor quantity. Antigen is normal while collagen-binding activity is markedly low. Interpret quantity and function separately.
Reasoning steps for option B
What would a primarily quantitative deficit predict?
A low antigen result would support reduced measured von Willebrand factor quantity.
Which results actually differ from that pattern?
Antigen is normal while collagen-binding activity is markedly low.
How do antigen 102% and collagen binding 24% oppose a quantity-only deficit?
Antigen is within its reference range, but adhesive activity is below range, indicating preserved measured quantity with impaired function.
C. Reduced platelet number with preserved protein function (Why this does not fit)
A low platelet count would support thrombocytopenia. Platelet count is normal and von Willebrand factor collagen binding is reduced. Do not substitute a count abnormality for an observed functional deficit.
Reasoning steps for option C
What would support quantitative platelet depletion?
A low platelet count would support thrombocytopenia.
Which supplied data point elsewhere?
Platelet count is normal and von Willebrand factor collagen binding is reduced.
Why is reduced platelet number inconsistent with the supplied measurements?
Platelet count is normal, while the abnormal result is von Willebrand collagen-binding activity, identifying a functional rather than numerical platelet problem.
D. Preserved protein quantity with impaired adhesive function (Best answer)
The antigen result is within range, supporting preserved measured quantity. Collagen-binding activity is low despite the preserved antigen concentration. High shear can deplete the largest effective multimers and impair adhesion without a low antigen result.
Reasoning steps for option D
Which result measures the amount of von Willebrand factor?
The antigen result is within range, supporting preserved measured quantity.
Which result tests a relevant functional property?
Collagen-binding activity is low despite the preserved antigen concentration.
How does the valve finding help explain the discrepancy?
High shear can deplete the largest effective multimers and impair adhesion without a low antigen result.
How can severe aortic stenosis explain normal antigen with low collagen binding?
Excessive shear can deplete the largest effective multimers and impair adhesion without lowering total measured antigen; multimer analysis remains pending.
E. Preserved protein quantity with normal adhesive function (Why this does not fit)
A functional result within its reference interval would support preserved performance in that assay. Collagen-binding activity is 24%, below the stated lower limit of 50%. A normal antigen cannot erase an abnormal functional assay.
Reasoning steps for option E
What would support preserved measured function?
A functional result within its reference interval would support preserved performance in that assay.
Is the functional result normal here?
Collagen-binding activity is 24%, below the stated lower limit of 50%.
Why does antigen 102% not make the collagen-binding assay normal?
Collagen binding is 24%, below the 50% lower reference limit, so normal quantity cannot negate the demonstrated functional abnormality.
Takeaway: Normal protein quantity can coexist with clinically important loss of function.
A. Correction of a congenital platelet-receptor mutation (Why this does not fit)
A congenital platelet-receptor defect can impair adhesion or aggregation. Valve replacement would not correct that mutation; the observed reversible change concerns multimer structure after relief of shear. Rapid reversibility can help distinguish an acquired process from an inherited defect.
Reasoning steps for option A
What can an inherited platelet-receptor disorder affect?
It can impair platelet adhesion or aggregation.
Would valve replacement correct the underlying mutation overnight?
It would not; the observed reversible change concerns multimer structure after relief of shear.
Why does overnight multimer recovery after valve replacement oppose a congenital receptor explanation?
Reducing valve shear can reverse an acquired multimer abnormality but does not correct an inherited platelet-receptor mutation.
B. Restoration of hepatic coagulation-factor synthesis (Why this does not fit)
Liver synthetic failure can produce deficiencies of several coagulation proteins. The largest von Willebrand multimers returned after gradient reduction, not a documented global synthetic defect. Match the explanation to the measured abnormality.
Reasoning steps for option B
What problem can impaired liver synthesis cause?
Liver synthetic failure can produce deficiencies of several coagulation proteins.
What specific laboratory feature recovered here?
The largest von Willebrand multimers returned after gradient reduction, not a documented global synthetic defect.
Why does recovery of large multimers not establish improved hepatic factor synthesis?
The measured recovery follows reduction of the valve gradient and concerns multimer structure, not a documented global hepatic synthetic defect.
C. Reduced shear-related degradation of large multimers (Best answer)
The abnormal valve gradient and associated shear were reduced. No additional procedure eradicated the bowel lesions. Less excessive shear permits recovery of the large-multimer pattern without requiring immediate disappearance of intestinal lesions.
Reasoning steps for option C
What changed immediately with the procedure?
The abnormal valve gradient and associated shear were reduced.
What did not change by local gastrointestinal treatment?
No additional procedure eradicated the bowel lesions.
What links the hemodynamic change to the laboratory result?
Less excessive shear permits recovery of the large-multimer pattern without requiring immediate disappearance of intestinal lesions.
Why can the multimer pattern improve before any further bowel treatment?
Valve replacement lowers excessive shear, reducing large-multimer degradation without requiring immediate eradication of the intestinal lesions.
D. Regression of every intestinal vascular lesion (Why this does not fit)
Local intestinal treatment can reduce bleeding at a treated site. Here, the laboratory change followed valve intervention without additional bowel treatment. A hemostatic response does not prove immediate lesion eradication.
Reasoning steps for option D
What can successful source treatment change?
It can reduce bleeding from a treated intestinal lesion.
Were the lesions treated again before the laboratory improvement?
No; the temporal change followed valve intervention without additional bowel treatment.
Why does the next-day laboratory improvement not prove regression of every ectasia?
The improvement followed valve intervention without further bowel treatment, so restored hemostatic protein structure is not evidence of lesion disappearance.
E. Immediate replacement of depleted iron stores (Why this does not fit)
Iron replacement supports recovery from iron deficiency. No iron replacement is described, and the reported improvement is in multimer structure. Iron balance and adhesive protein structure are distinct outcomes.
Reasoning steps for option E
What does iron replacement improve?
Iron replacement supports recovery from iron deficiency.
Can valve intervention itself explain overnight iron repletion?
No iron replacement is described, and the reported improvement is in multimer structure.
Why is return of large multimers not evidence of restored iron stores?
The reported change is in adhesive protein structure after valve treatment; no iron replacement or measured iron-store recovery is described.
Takeaway: Relieving excessive shear can improve hemostasis before intestinal lesions disappear.
A. Limit follow-up to repeat ablation of visible bowel lesions (Why this does not fit)
Repeat ablation can treat accessible responsible lesions. Residual valve leakage and persistent multimer loss suggest a continuing hemostatic contributor. Recurrent bleeding may require more than local lesion treatment.
Reasoning steps for option A
What can repeat ablation accomplish?
Repeat ablation can treat accessible responsible lesions.
Which additional abnormality would be left unaddressed?
Residual valve leakage and persistent multimer loss suggest a continuing hemostatic contributor.
What would a bowel-ablation-only plan leave unexplained after TAVI?
Persistent paravalvular regurgitation and depleted large multimers suggest a continuing valve-related hemostatic contributor beyond the accessible intestinal lesions.
B. Exclude Heyde-related bleeding because a valve was implanted (Why this does not fit)
Valve replacement can reduce bleeding in many patients with the relevant valve-related syndrome. Residual paravalvular leakage and depleted large multimers remain despite implantation. Completion of a procedure does not prove that its intended physiologic result was achieved.
Reasoning steps for option B
What benefit can TAVI provide?
Valve replacement can reduce bleeding in many patients with the relevant valve-related syndrome.
What limits that inference in this patient?
Residual paravalvular leakage and depleted large multimers remain despite implantation.
Why does valve implantation alone not exclude persistent Heyde-related bleeding?
Residual paravalvular leakage and continued large-multimer depletion show that the intended physiologic correction may be incomplete despite implantation.
C. Limit follow-up to iron replacement without source reassessment (Why this does not fit)
Iron replacement replenishes depleted stores caused by ongoing or previous loss. Recurrent melena, visible lesions and persistent hemostatic abnormalities remain. Improving iron stores does not establish that the cause of loss is controlled.
Reasoning steps for option C
Why is iron treatment useful?
Iron replacement replenishes depleted stores caused by ongoing or previous loss.
What current findings require more than replacement?
Recurrent melena, visible lesions and persistent hemostatic abnormalities remain.
Why would improved iron stores not settle the cause of recurrent melena?
Replacement treats the deficit, but recurrent melena, vascular ectasias and persistent hemostatic abnormalities still require reassessment.
D. Attribute the recurrence to a new inherited bleeding disorder (Why this does not fit)
Some inherited primary-hemostasis defects impair platelet adhesion. The patient has residual valve dysfunction with persistent selective multimer loss after a valve-related bleeding presentation. Prefer the demonstrated acquired process over a newly assumed inherited disorder.
Reasoning steps for option D
Why can inherited disorders cause mucosal bleeding?
Some inherited primary-hemostasis defects impair platelet adhesion.
What more direct acquired explanation is supplied?
The patient has residual valve dysfunction with persistent selective multimer loss after a valve-related bleeding presentation.
Why is an acquired valve-related process more supported than a new inherited disorder?
Residual valve dysfunction accompanies persistent selective large-multimer loss in a patient already presenting with valve-associated bleeding.
E. Coordinate repeat gastrointestinal and valve-team assessment (Best answer)
Enteroscopy identifies vascular ectasias in a patient with recurrent melena. Residual paravalvular regurgitation accompanies continued loss of large multimers. Both the gastrointestinal sources and residual valve dysfunction need evaluation rather than assuming that prior TAVI guaranteed cure.
Reasoning steps for option E
What shows that a gastrointestinal bleeding substrate persists?
Enteroscopy identifies vascular ectasias in a patient with recurrent melena.
What suggests the hemostatic contributor may also persist?
Residual paravalvular regurgitation accompanies continued loss of large multimers.
What scope of reassessment follows?
Both the gastrointestinal sources and residual valve dysfunction need evaluation rather than assuming that prior TAVI guaranteed cure.
Why should recurrent bleeding prompt both gastrointestinal and valve-team review?
Ectasias remain a bleeding substrate, while residual regurgitation and multimer depletion suggest ongoing hemostatic dysfunction requiring valve reassessment.
Takeaway: Reassess the physiologic result of valve treatment when bleeding returns.
A. Start octreotide before assessing the gastrointestinal source (Why this does not fit)
Selected refractory angiodysplasia-related bleeding can justify systemic treatment. The current gastrointestinal source and response to source-directed care are unknown. Renal disease is an association, not proof of a specific bleeding lesion.
Reasoning steps for option A
What clinical setting supports octreotide consideration?
Selected refractory angiodysplasia-related bleeding can justify systemic treatment.
What has not yet been established here?
The current gastrointestinal source and response to source-directed care are unknown.
Why does chronic kidney disease not establish an indication for octreotide before source evaluation?
Renal disease is associated with bleeding risk but does not identify the current gastrointestinal lesion or establish refractory angiodysplasia.
B. Increase erythropoiesis-stimulating treatment without source evaluation (Why this does not fit)
Reduced erythropoietin activity can impair red-cell production. Marked iron depletion and maroon stool support an additional blood-loss process. A chronic cause of anemia does not exclude a new cause.
Reasoning steps for option B
Why could kidney disease contribute to anemia?
Reduced erythropoietin activity can impair red-cell production.
What new evidence is not explained by that mechanism alone?
Marked iron depletion and maroon stool support an additional blood-loss process.
Why should falling ferritin and maroon stools not be treated solely by increasing erythropoietic therapy?
Reduced erythropoietin can contribute to anemia, but ferritin of 9 ng/mL and maroon stool indicate superimposed iron depletion and gastrointestinal loss.
C. Investigate gastrointestinal loss and replace deficient iron (Best answer)
The markedly low ferritin indicates depleted stores rather than an isolated reduction in erythropoietin effect. Intermittent maroon stool provides clinical evidence of gastrointestinal blood loss. Renal anemia can coexist with gastrointestinal bleeding, so source evaluation and iron replacement are needed.
Reasoning steps for option C
What do the changing iron measurements show?
The markedly low ferritin indicates depleted stores rather than an isolated reduction in erythropoietin effect.
What finding supports a bleeding source?
Intermittent maroon stool provides clinical evidence of gastrointestinal blood loss.
How should kidney disease affect the plan?
Renal anemia can coexist with gastrointestinal bleeding, so source evaluation and iron replacement are needed.
How do the new findings change management despite established renal anemia?
The fall in ferritin to 9 ng/mL and intermittent maroon stools require gastrointestinal source evaluation and iron replacement in addition to recognizing renal anemia.
D. Exclude bleeding because platelet count is normal (Why this does not fit)
A platelet count measures circulating platelet number. Vascular lesions can bleed with a normal count, and platelet number does not establish normal function. Separate platelet quantity from the presence of an anatomical source.
Reasoning steps for option D
What does the platelet count measure?
It measures circulating platelet number.
Does that test exclude a bleeding intestinal lesion?
No; vascular lesions can bleed with a normal count, and platelet number does not establish normal function.
Why does a normal platelet count not dismiss the maroon stools as nonhemorrhagic?
Normal platelet number neither excludes a bleeding vascular lesion nor establishes normal platelet function; the symptom still needs source evaluation.
E. Attribute all iron loss to inadequate dietary intake (Why this does not fit)
Insufficient intake can contribute to depleted stores. Maroon stools provide evidence of gastrointestinal bleeding. Do not explain away a bleeding symptom with a less direct hypothesis.
Reasoning steps for option E
How can low intake affect iron status?
Insufficient intake can contribute to depleted stores.
Which symptom demands investigation beyond intake?
Maroon stools provide evidence of gastrointestinal bleeding.
Why is dietary insufficiency alone an inadequate explanation for this iron decline?
Maroon stools provide direct clinical evidence of gastrointestinal bleeding, requiring investigation beyond a hypothesis of poor intake.
Takeaway: Renal anemia and gastrointestinal blood loss can coexist.
A. Empiric small-bowel arterial embolization (Why this does not fit)
Arterial embolization can treat a localized significant active bleed. There is no active major hemorrhage or identified arterial target. Diffuse recurrent mucosal bleeding is not an indication for blind embolization.
Reasoning steps for option A
When can embolization be effective?
Arterial embolization can treat a localized significant active bleed.
What is missing for that approach now?
There is no active major hemorrhage or identified arterial target.
Why is empiric small-bowel embolization not justified by this diffuse recurrence?
There is no active major hemorrhage or localized arterial target, so diffuse mucosal lesions do not support blind arterial intervention.
B. Iron replacement as the only continuing strategy (Why this does not fit)
Iron replacement treats ongoing or accumulated iron deficiency. She still requires repeated red-cell transfusions and iron despite treatment and wants to reduce recurrent loss. Substantial persistent burden can justify discussion of additional therapy.
Reasoning steps for option B
What does iron replacement contribute despite this patient's ongoing transfusion burden?
Replacement treats iron deficiency from ongoing or accumulated loss, but does not by itself establish control of the recurrent small-bowel bleeding.
What demonstrates that support alone has not met this goal?
She still requires repeated red-cell transfusions and iron despite treatment and wants to reduce recurrent loss.
Why discuss additional therapy rather than rely on iron alone after eight red-cell units?
Substantial transfusion and intravenous-iron needs persist despite endoscopic treatment, demonstrating a recurrent burden not adequately addressed by replacement alone.
C. Empiric right hemicolectomy (Why this does not fit)
Segmental surgery can address selected accurately localized refractory bleeding. Here, the documented lesions are diffusely distributed in the small bowel, not confined to the right colon. The proposed treatment field must match the bleeding distribution.
Reasoning steps for option C
When can resection help?
It can address selected accurately localized refractory bleeding.
Where are the demonstrated lesions here?
They are diffusely distributed in the small bowel, not confined to the right colon.
Why would right hemicolectomy not match the demonstrated disease?
The confirmed lesions are diffusely distributed in the small bowel rather than localized to the right colon, so the proposed resection would miss them.
D. Repeat ablation of the quiet cecum (Why this does not fit)
A responsible accessible target needs to be identified. No further focal lesion is currently amenable to treatment, and the documented disease is small-bowel. Do not repeat a familiar procedure without a suitable target.
Reasoning steps for option D
What is necessary for useful focal ablation?
A responsible accessible target needs to be identified.
What current target does the case provide?
No further focal lesion is currently amenable to treatment, and the documented disease is small-bowel.
Why is repeat cecal ablation not a source-directed solution here?
The documented disease is small-bowel and no further focal lesion is amenable to therapy; the quiet cecum provides no responsible target.
E. Specialist-directed long-acting octreotide (Best answer)
Substantial transfusion and iron needs continue despite endoscopic therapy. The disease is diffuse and no further focal target is currently amenable to treatment. Long-acting octreotide has randomized-trial evidence for reducing support requirements in selected angiodysplasia-related anemia.
Reasoning steps for option E
What establishes refractory disease rather than an incidental finding?
Substantial transfusion and iron needs continue despite endoscopic therapy.
Why is another focal procedure not the obvious solution?
The disease is diffuse and no further focal target is currently amenable to treatment.
What evidence-based systemic option fits this goal?
Long-acting octreotide has randomized-trial evidence for reducing support requirements in selected angiodysplasia-related anemia.
Which features match the population supporting specialist-directed long-acting octreotide?
Confirmed diffuse angioectasias cause persistent transfusion and iron needs despite repeated endoscopic treatment, with no further treatable focal target and no acute major hemorrhage.
Takeaway: Trial-supported recurrence therapy belongs to selected refractory disease, not every vascular lesion.
A. Red-cell support decreased by 10.2 units; iron support was unchanged (Why this does not fit)
The endpoint uses a unit count that includes red-cell support. Parenteral-iron support contributes to the same composite outcome, so its change is not separated here. Read the endpoint definition before translating a treatment effect.
Reasoning steps for option A
Why might the number be mistaken for a transfusion-only result?
The endpoint uses a unit count that includes red-cell support.
What other component is explicitly included?
Parenteral-iron support contributes to the same composite outcome, so its change is not separated here.
Why cannot the adjusted 10.2-unit reduction be assigned entirely to red cells?
The outcome combines red-cell and study-defined parenteral-iron units, so neither the red-cell reduction nor unchanged iron use is established separately.
B. Combined support decreased; the remaining intestinal lesions were eradicated (Why this does not fit)
Effective treatment can reduce bleeding and subsequent support requirements. However, support use is not a direct measurement of whether every vascular lesion has disappeared. An improved clinical support endpoint does not prove anatomical cure.
Reasoning steps for option B
What can effective lesion treatment accomplish?
It can reduce bleeding and subsequent support requirements.
Was lesion eradication measured by the stated endpoint?
No; support use is not a direct measurement of whether every vascular lesion has disappeared.
Why does reduced combined support not demonstrate eradication of intestinal lesions?
Support consumption measures clinical burden, not lesion disappearance; the stated endpoint contains no anatomical cure assessment.
C. Combined support decreased; the red-cell-only reduction is not specified (Best answer)
The primary endpoint combines two types of support rather than measuring red-cell transfusions alone. The interval for the adjusted difference lies above zero, supporting a lower combined support requirement with octreotide. The 10.2-unit reduction cannot be described as 10.2 fewer red-cell units without a separate red-cell analysis.
Reasoning steps for option C
What does the primary endpoint count?
The primary endpoint combines two types of support rather than measuring red-cell transfusions alone.
What does the reported confidence interval indicate?
The interval for the adjusted difference lies above zero, supporting a lower combined support requirement with octreotide.
What cannot be inferred from that number?
The 10.2-unit reduction cannot be described as 10.2 fewer red-cell units without a separate red-cell analysis.
What can the positive 2.4-to-18.1 interval establish without a component analysis?
It supports reduced combined support with octreotide, but the 10.2-unit adjusted effect cannot be interpreted as a red-cell-only reduction.
D. Combined support was equivalent; the interval includes uncertainty (Why this does not fit)
An interval spanning zero would not establish a directional difference at that confidence level. The interval is 2.4 to 18.1 units, entirely above zero for the reported reduction. Uncertainty about effect size is not the same as evidence of equivalence.
Reasoning steps for option D
When does uncertainty preclude a demonstrated directional difference?
An interval spanning zero would not establish a directional difference at that confidence level.
Does this interval span zero?
The interval is 2.4 to 18.1 units, entirely above zero for the reported reduction.
Why is uncertainty within 2.4 to 18.1 units not evidence of equivalent support requirements?
The whole interval is above zero for the reduction, supporting a directional benefit while leaving uncertainty about its magnitude.
Takeaway: An endpoint determines what a treatment-effect number can legitimately mean.
A. Response criterion met; overt bleeding has not ceased (Best answer)
The count falls by five from a baseline of ten, which is a 50% reduction. An inclusive threshold of at least 50% includes exactly 50%. Five episodes with visible blood demonstrate continuing overt bleeding.
Reasoning steps for option A
What is the reduction in episode count?
The count falls by five from a baseline of ten, which is a 50% reduction.
Does the boundary meet the specified trial definition?
Yes. At least 50% includes exactly 50%.
Does meeting that threshold establish cessation?
No. Five episodes with visible blood demonstrate continuing overt bleeding.
How can this patient meet the trial response endpoint yet continue overt bleeding?
Ten episodes falling to five is exactly a 50% decrease and meets the inclusive threshold, while visible blood in all five remaining episodes excludes cessation.
B. Response criterion met; overt bleeding has ceased (Why this does not fit)
Ten episodes falling to five meets the inclusive 50% threshold. Five follow-up episodes still contained visible blood. A partial response and complete cessation are different outcomes.
Reasoning steps for option B
Why does the patient qualify as a responder?
Ten episodes falling to five meets the inclusive 50% threshold.
What rules out bleeding cessation?
Five follow-up episodes still contained visible blood.
Why does meeting the 50% threshold not establish cessation in this follow-up year?
The count meets the response criterion, but five visibly bloody episodes document continuing overt bleeding.
C. Response criterion not met; overt bleeding has ceased (Why this does not fit)
A period without further overt episodes would support cessation. The 50% reduction meets the response definition, and the remaining visibly bloody episodes exclude cessation. Evaluate the response threshold and the residual disease separately.
Reasoning steps for option C
What would justify calling the bleeding fully controlled?
A period without further overt episodes would support cessation.
Which two observations defeat this classification?
The 50% reduction meets the response definition, and the remaining visibly bloody episodes exclude cessation.
How should the response classification and cessation claim each be checked?
The 50% reduction satisfies the response definition, whereas the five episodes with visible blood disprove cessation, making both parts of this option incorrect.
D. Response criterion not met; overt bleeding has not ceased (Why this does not fit)
An exclusive threshold above 50% would exclude a reduction of exactly 50%. The definition uses at least 50%, so the boundary qualifies. Apply the stated endpoint rather than substituting a stricter one.
Reasoning steps for option D
Why might the patient be incorrectly classified as a nonresponder?
An exclusive threshold above 50% would exclude a reduction of exactly 50%.
What threshold was actually supplied?
The definition uses at least 50%, so the boundary qualifies.
Why does exactly 50% qualify even though five overt episodes remain?
The definition says at least 50%, so the patient is a responder; persistent overt bleeding does not change that inclusive response threshold.
Takeaway: A responder may still have clinically important bleeding.
A. Increase the dose to obtain complete bleeding cessation (Why this does not fit)
More intensive treatment can sometimes improve efficacy. Possible treatment-related neuropathy has already appeared at the current dose. Do not escalate a potentially harmful exposure merely to improve a partial response.
Reasoning steps for option A
Why might a dose increase be considered during incomplete response?
More intensive treatment can sometimes improve efficacy.
What finding argues against escalation here?
Possible treatment-related neuropathy has already appeared at the current dose.
Why should a partial bleeding response not prompt thalidomide dose escalation now?
New foot numbness and reduced vibration suggest neuropathy at the current dose, making increased potentially neurotoxic exposure inappropriate.
B. Interrupt thalidomide and promptly evaluate possible drug-related neuropathy (Best answer)
New distal sensory symptoms and examination abnormalities are compatible with peripheral neuropathy. The deficit began after a drug known to cause potentially persistent peripheral nerve injury was introduced. Reduced bleeding does not justify ignoring possible neurotoxicity; treatment should be interrupted and assessed promptly.
Reasoning steps for option B
Which new finding raises a treatment safety concern?
New distal sensory symptoms and examination abnormalities are compatible with peripheral neuropathy.
Why is the temporal association important?
The deficit began after a drug known to cause potentially persistent peripheral nerve injury was introduced.
How should the bleeding response affect the decision?
Reduced bleeding does not justify ignoring possible neurotoxicity; treatment should be interrupted and assessed promptly.
Why interrupt thalidomide despite fewer bleeding episodes at ten weeks?
New bilateral distal sensory abnormalities after treatment raise concern for potentially persistent drug-related neuropathy and require prompt evaluation rather than continued exposure for bleeding benefit.
C. Add symptomatic therapy while continuing the same dose (Why this does not fit)
Symptomatic treatment may reduce discomfort associated with neuropathic symptoms. The patient would continue the potentially neurotoxic drug despite new sensory loss. Relieving symptoms is not equivalent to controlling drug-related injury.
Reasoning steps for option C
What can symptomatic treatment accomplish?
Symptomatic treatment may reduce discomfort associated with neuropathic symptoms.
What causative exposure would remain unaddressed?
The patient would continue the potentially neurotoxic drug despite new sensory loss.
Why would symptom relief alone not address the new sensory loss?
Continuing thalidomide leaves the potentially neurotoxic exposure in place; reduced discomfort does not establish control of drug-related nerve injury.
D. Continue the same dose and reassess sensation in three months (Why this does not fit)
The bleeding frequency has improved on treatment. New objective sensory abnormalities raise concern for a toxicity that can persist or progress. A clinical benefit does not cancel a potentially serious adverse effect.
Reasoning steps for option D
What might make continued treatment appealing?
The bleeding frequency has improved on treatment.
What makes delayed reassessment unsafe?
New objective sensory abnormalities raise concern for a toxicity that can persist or progress.
Why is waiting three months unsafe despite improved bleeding frequency?
Objective new sensory abnormalities may reflect toxicity that can persist or progress, so the bleeding benefit does not justify delayed assessment.
Takeaway: Possible thalidomide neuropathy needs prompt action even when bleeding improves.
A. Stop aspirin indefinitely because a vascular lesion bled (Why this does not fit)
Avoiding antiplatelet exposure may appear to reduce one contributor to rebleeding. A prior myocardial infarction establishes a secondary-prevention indication that should not be discarded automatically after controlled bleeding. Balance bleeding control against the indication for the antithrombotic drug.
Reasoning steps for option A
Why might permanent cessation seem protective?
Avoiding antiplatelet exposure may appear to reduce one contributor to rebleeding.
Which competing risk matters for this patient?
A prior myocardial infarction establishes a secondary-prevention indication that should not be discarded automatically after controlled bleeding.
Why should controlled angioectasia bleeding not automatically end aspirin after myocardial infarction?
Prior myocardial infarction establishes a secondary-prevention indication that remains relevant once the bleeding source is treated and hemostasis confirmed.
B. Defer aspirin until repeat capsule endoscopy is negative (Why this does not fit)
Capsule endoscopy can investigate persistent suspected small-bowel bleeding after an appropriate evaluation. A colonic source was treated with confirmed hemostasis and there is no continuing hemorrhage. Do not require an unrelated negative investigation before indicated secondary prevention resumes.
Reasoning steps for option B
When can capsule examination be indicated?
Capsule endoscopy can investigate persistent suspected small-bowel bleeding after an appropriate evaluation.
What is already established in this case?
A colonic source was treated with confirmed hemostasis and there is no continuing hemorrhage.
Why is a negative capsule study not required before aspirin resumption here?
The demonstrated cecal source has been treated with confirmed hemostasis and no continuing hemorrhage; an unrelated small-bowel study is not the restart criterion.
C. Resume aspirin on the day hemostasis is confirmed (Best answer)
Aspirin is prescribed for secondary cardiovascular prevention after myocardial infarction, not primary prevention. The bleeding source has been treated and hemostasis is endoscopically confirmed. After such an interruption, resume cardiac aspirin on the day endoscopic hemostasis is confirmed.
Reasoning steps for option C
What is the reason for aspirin use?
Aspirin is prescribed for secondary cardiovascular prevention after myocardial infarction, not primary prevention.
What condition permits the recommended resumption after interruption?
The bleeding source has been treated and hemostasis is endoscopically confirmed.
What timing does the guideline suggest?
After such an interruption, resume cardiac aspirin on the day endoscopic hemostasis is confirmed.
Which two facts support restarting aspirin on the day of confirmed hemostasis?
Aspirin is for secondary prevention after myocardial infarction, and endoscopic hemostasis is confirmed after interruption, meeting the stated guideline restart condition.
D. Defer aspirin until ferritin returns to its reference range (Why this does not fit)
Ferritin helps assess replenishment after blood loss. Confirmed hemostasis, not complete iron-store recovery, is the relevant restart condition here. Separate recovery of iron stores from cardiovascular prevention decisions.
Reasoning steps for option D
Why might iron recovery be considered in follow-up?
Ferritin helps assess replenishment after blood loss.
Does ferritin define the recommended aspirin restart point?
Confirmed hemostasis, not complete iron-store recovery, is the relevant restart condition here.
Why should ferritin normalization not determine the aspirin restart date?
Iron-store recovery is separate from bleeding control; confirmed endoscopic hemostasis is the relevant restart condition for this secondary-prevention indication.
Takeaway: Controlled bleeding does not automatically end a secondary-prevention aspirin indication.
A. Continue the unchanged oral iron schedule (Why this does not fit)
Oral iron can replenish deficient stores without an infusion. Repeated vomiting persists despite an attempted schedule adjustment. An effective replacement plan must be deliverable and tolerated.
Reasoning steps for option A
What benefit does oral iron offer when tolerated?
Oral iron can replenish deficient stores without an infusion.
What prevents that benefit in this patient?
Repeated vomiting persists despite an attempted schedule adjustment.
Why is continuing the same oral schedule unlikely to correct ferritin 8 ng/mL?
Recurrent vomiting persists despite a less frequent dosing trial, preventing a tolerated effective oral replacement course.
B. Begin recurring red-cell transfusions for iron repletion (Why this does not fit)
Red-cell transfusion can address selected clinically important red-cell deficits and oxygen-delivery needs. The supplied problem is failure of iron replacement, not shock or another urgent transfusion indication. Do not use repeated transfusion as a routine substitute for feasible iron replacement.
Reasoning steps for option B
What immediate problem can red-cell transfusion treat?
Red-cell transfusion can address selected clinically important red-cell deficits and oxygen-delivery needs.
What is the specific question in this stable patient?
The supplied problem is failure of iron replacement, not shock or another urgent transfusion indication.
Why choose feasible iron replacement rather than recurring transfusions in this stable patient?
The demonstrated problem is depleted iron with oral intolerance, not shock or another supplied urgent transfusion indication; repeated transfusion is not routine iron replacement.
C. Use intravenous iron replacement (Best answer)
The low ferritin shows that iron stores remain depleted. Recurrent vomiting prevents a tolerated effective oral replacement course despite a dosing adjustment. Intravenous iron is appropriate when oral iron is not tolerated, while the response and any recurrent blood loss are followed.
Reasoning steps for option C
What ongoing deficit is demonstrated?
The low ferritin shows that iron stores remain depleted.
Why has the oral strategy failed?
Recurrent vomiting prevents a tolerated effective oral replacement course despite a dosing adjustment.
Which route addresses that limitation?
Intravenous iron is appropriate when oral iron is not tolerated, while the response and any recurrent blood loss are followed.
How does intravenous iron address the failed oral strategy without ending follow-up?
It bypasses oral intolerance to replenish the persistently depleted stores, while response and any recurrent blood loss still require monitoring.
D. Stop iron therapy because the lesion was treated (Why this does not fit)
Endoscopic treatment can prevent additional loss from the treated source. Stores remain depleted and need replacement despite source control. Stopping loss does not itself repair the accumulated deficit.
Reasoning steps for option D
What does successful local hemostasis accomplish?
Endoscopic treatment can prevent additional loss from the treated source.
What does the ferritin show after treatment?
Stores remain depleted and need replacement despite source control.
Why does successful lesion treatment not justify stopping iron with ferritin 8 ng/mL?
Local hemostasis prevents further loss from the treated source but does not replenish the already depleted iron stores.
Takeaway: Intravenous iron can address oral intolerance; continued monitoring still matters.
